Table 1.
Sociodemographic of and tumor characteristics in patients (n = 128).
| Variables | n (%) |
| Age (yr) | |
| ≤ 30 | 2 (1.56) |
| 31 – 40 | 22 (17.19) |
| 41 – 50 | 47 (36.72) |
| 51 – 60 | 29 (22.66) |
| 61 – 70 | 17 (13.28) |
| > 70 | 11 (8.59) |
| Ethnicity | |
| White | 65 (50.78) |
| Non-White | 61 (47.66) |
| NDa | 2 (1.56) |
| Menopausal status | |
| Pre-menopausal | 58 (45.31) |
| Post-menopausal | 64 (50.00) |
| NDa | 6 (4.69) |
| FH breast cancer | |
| Negative | 75 (58.59) |
| 1° degree* | 11 (8.59) |
| 2° and/or 3° degrees | 27 (21.10) |
| NDa | 15 (11.72) |
| Tumor size | |
| ≤ 2 cm | 57 (44.53) |
| > 2 cm a ≤ 5 cm | 40 (31.25) |
| > 5 cm | 3 (2.34) |
| NDa | 28 (21,88) |
| Elston Grade | |
| I | 28 (21.87) |
| II | 61 (47.66) |
| III | 23 (17.97) |
| NDa | 16 (12.50) |
| Lymph node commitment | |
| Negative | 45 (35.16) |
| Positive | 49 (38.28) |
| NDa | 34 (26.56) |
| ER | |
| Positive | 52 (40.63) |
| Negative | 26 (20.31) |
| NDa | 50 (39.06) |
| PR | |
| Positive | 51 (39.84) |
| Negative | 28 (21.88) |
| NDa | 49 (38.28) |
| HER2 | |
| Negative | 36 (28.12) |
| Positive | 32 (25.00) |
| NDa | 60 (46.88) |
NDa = no data; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor type 2; FH = family history; *mother and/or sister.